Cytokinetics Announces Additional Results From COSMIC-HF to Be Presented at the American Heart Association Scientific Session...
November 06 2017 - 4:20PM
Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that
additional results from COSMIC-HF
(
Chronic
Oral
Study
of
Myosin Activation
to
Increase
Contractility
in
Heart
Failure), a
Phase 2 trial evaluating omecamtiv mecarbil in patients
with chronic heart failure, will be presented in an Abstract Rapid
Fire Oral presentation at the American Heart Association Scientific
Sessions 2017 from November 11-15 in Anaheim, Calif.
Abstract Title: Treatment With Omecamtiv
Mecarbil, a Cardiac Myosin Activator, Improves NT-proBNP in
Patients With Chronic Heart Failure: A Responder Analysis From
COSMIC-HF (632)Speaker: John Teerlink, M.D., Professor of Clinical
Medicine at the University of California San Francisco and Director
of Heart Failure at the San Francisco Veterans Affairs Medical
CentersSession Title: A Whirlwind Tour of Insights into CHF and
CardiomyopathyLocation: Anaheim Convention Center, Clinical II
Forum, Science and Technology HallDate: Monday, November 13,
2017Time: 10:10 – 11:20 AM PST
About Omecamtiv Mecarbil
Omecamtiv mecarbil is a novel cardiac myosin
activator. Cardiac myosin is the cytoskeletal motor protein in the
cardiac muscle cell that is directly responsible for converting
chemical energy into the mechanical force resulting in cardiac
contraction. Cardiac myosin activators are thought to accelerate
the rate-limiting step of the myosin enzymatic cycle and shift the
enzymatic cycle in favor of the force-producing state. Preclinical
research has shown that cardiac myosin activators increase
contractility in the absence of changes in intracellular calcium in
cardiac myocytes.
Omecamtiv mecarbil is being developed by Amgen
in collaboration with Cytokinetics. Amgen holds an exclusive,
worldwide license to omecamtiv mecarbil and related compounds,
subject to Cytokinetics’ specified development and
commercialization rights. Amgen has also entered an alliance with
Servier for exclusive commercialization rights in Europe as well as
the Commonwealth of Independent States, including Russia. Servier
contributes funding for development and provides strategic support
to the program.
About Cytokinetics
Cytokinetics is a late-stage
biopharmaceutical company focused on discovering, developing and
commercializing first-in-class muscle activators as potential
treatments for debilitating diseases in which muscle performance is
compromised and/or declining. As a leader in muscle biology and the
mechanics of muscle performance, the company is developing small
molecule drug candidates specifically engineered to increase muscle
function and contractility. Cytokinetics’ lead drug candidate
is tirasemtiv, a fast skeletal muscle troponin activator
(FSTA). Tirasemtiv is the subject of VITALITY-ALS, an
international Phase 3 clinical trial in patients with
ALS. Tirasemtiv has been granted orphan drug designation
and fast track status by the U.S. Food and Drug
Administration (FDA) and orphan medicinal product designation
by the European Medicines Agency for the potential
treatment of ALS. Cytokinetics is preparing for the
potential commercialization of tirasemtiv in North
America and Europe and has granted an option
to Astellas Pharma Inc. (“Astellas”) for development and
commercialization in other countries. Cytokinetics is
collaborating with Astellas to develop CK-2127107, a
next-generation FSTA. CK-2127107 has been granted orphan drug
designation by the FDA for the potential treatment of
SMA. CK-2127107 is the subject of three ongoing Phase 2 clinical
trials enrolling patients with spinal muscular atrophy, chronic
obstructive pulmonary disease and ALS. Astellas is also conducting
a Phase 1b clinical trial of CK-2127107 in elderly adults with
limited mobility. Cytokinetics is collaborating
with Amgen Inc. (“Amgen”) to develop omecamtiv
mecarbil, a novel cardiac muscle activator. Omecamtiv
mecarbil is the subject of GALACTIC-HF, an international Phase
3 clinical trial in patients with heart
failure. Amgen holds an exclusive worldwide license to
develop and commercialize omecamtiv mecarbil with a
sublicense held by Servier for commercialization
in Europe and certain other countries. Astellas holds an
exclusive worldwide license to develop and commercialize
CK-2127107. Licenses held by Amgen and Astellas are
subject to Cytokinetics' specified co-development and
co-commercialization rights. For additional information
about Cytokinetics,
visit http://www.cytokinetics.com/.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the "Act"). Cytokinetics disclaims any
intent or obligation to update these forward-looking statements,
and claims the protection of the Act's Safe Harbor for
forward-looking statements. Examples of such statements include,
but are not limited to, statements relating
to Cytokinetics' and its partners' research and
development activities of Cytokinetics’ product candidates and
preparations for the potential commercialization
of tirasemtiv. Such statements are based on management's
current expectations, but actual results may differ materially due
to various risks and uncertainties, including, but not limited to
the risks related to Cytokinetics' business outlined
in Cytokinetics' filings with the Securities and
Exchange Commission. Forward-looking statements are not guarantees
of future performance, and Cytokinetics' actual results
of operations, financial condition and liquidity, and the
development of the industry in which it operates, may differ
materially from the forward-looking statements contained in this
press release. Any forward-looking statements
that Cytokinetics makes in this press release speak only
as of the date of this press
release. Cytokinetics assumes no obligation to update its
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
Contact:CytokineticsDiane
WeiserVice President, Corporate Communications, Investor
Relations(415) 290-3060
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Apr 2023 to Apr 2024